
Farewell dinner for our amazing postdoc Guillaume🥹Thank you for the science and all the good laughs at the bench. We'll miss you so much.

@TischCancer @SinaiImmunol Laboratory of Dr. Nina Bhardwaj Immunology & Immunotherapy Posts by Lab Members

Farewell dinner for our amazing postdoc Guillaume🥹Thank you for the science and all the good laughs at the bench. We'll miss you so much.

Spatiotemporal dynamics of adoptively transferred stem-like CD8+ T cells in the tumor microenvironment following vaccination cell.com/cell-reports-medici… @CellRepMed

Review @NatureCancer @Dr_Nick_Bikes @ScientistBecs Natural killer cell inflammatory circuits in antitumor immunity nature.com/articles/s43018-0…

Congratulations to PICI researcher @RobertBlelloch, MD, PhD, and his @UCSF colleagues on new research showing how lab-grown dendritic cells can be “dressed” with a patient’s own tumor material to train T cells to target and kill cancer cells. Read more here: cancer.ucsf.edu/news/2026/08…

Submit an abstract by December 7 for the AACR IO Conference on Discovery and Innovation in Cancer Immunology (February 28-March 3, 2027; Los Angeles), chaired by Nina Bhardwaj, Elizabeth M. Jaffee, and Antoni Ribas. Learn more: brnw.ch/21x70hN #AACRIO27 @BhardwajLab

STAT3 acts as a cytokine-sensing switch in NK cells, integrating IL-15 and type I IFN signals to shape antiviral responses @SunLab_Official @SciImmunology @MSKCancerCenter @SimonGrassmann science.org/doi/10.1126/scii…

🎬 Ready for your research to take center stage? Abstract submission for #IMMUNOLOGY2027™ in Los Angeles is OPEN! Share your breakthrough science and connect with global experts. Submit by the Nov 17th deadline: immunology2027.aai.org/absta….

🦉The vaccine got T cells in — but mostly not the ones that mattered. CCL21-engineered dendritic cells did what they were designed to do: they pulled new T-cell clones into resistant NSCLC tumors. Yet among 19 evaluable patients there were no objective responses. The more revealing result came later. Many recruited clones disappeared by day 42, while the minority that persisted were more likely to show tumor-reactive signatures and expanded more strongly in patients with stable disease. Meanwhile, suppressive IL1B⁺/SPP1⁺ macrophage signaling remained. That shifts the bottleneck. In a “cold” tumor, getting more T cells through the door may not be enough. Which clones arrive, whether they recognize tumor, and whether the microenvironment lets them survive may matter more than infiltration itself. Small, uncontrolled phase I data, and tumor specificity was inferred rather than directly proven—but the biology is a useful warning against treating T-cell density as a surrogate for effective immunity. #immunotherapy #T_cell #dendritic_cell 👉doi.org/10.1038/s41467-026-7…

Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte–mediated cancer immunotherapy @ScienceAdvances science.org/doi/10.1126/scia…

Retreat season is here! Next Thursday at the PrIISM-IGI-CVRI Retreat, our postdoc Ross Ward @RossWWard44 is giving a talk in the 10-11 AM Trainee Talks session, and a few of us will be around with posters too. Come find us, we'd love to connect! #PrIISMCVRIIGI2026

The next big questions in immunology dlvr.it/TVf2tH

Lipid nanoparticles optimized for large RNA cargo and tissue targeting enhance in vivo genome editing nature.com/articles/s41587-0…

Ward, Kar, Balan & @BhardwajLab review how conventional cDC1s coordinate antitumor immunity through cross-presentation, immune cell networking, and spatial organization in tumors. hubs.la/Q04v-QF20 Part of our #CancerImmunotherapy 2026 👉 hubs.la/Q04v_rXD0 #CSHAsia

The @US_FDA approved the HER2-targeted therapy zanidatamab plus chemotherapy (with tislelizumab for some patients) as first-line treatment for certain HER2-positive unresectable advanced gastric, gastroesophageal junction, or esophageal cancers: Journals: brnw.ch/21x5dZf

Awesome results from what will soon be the next FDA-approved #CancerVaccine, making people live longer without cancer! modernatx.com/ir-insights-ph…

independent.co.uk/news/uk/ho… Nina Bhardwaj, MD, PhD, notes that this is an exciting time for cancer immunotherapy. @BhardwajLab @IcahnMountSinai